91.74
+8.54%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Inhibrx Biosciences
From its filings with the US Securities and Exchange Commission
Inhibrx Biosciences is based in La Jolla, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker INBX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $1.3m and a net loss of $140.1m. At that date it held total assets of $146.5m and shareholders' equity of $8.0m.
We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential.
On May 29, 2024, Inhibrx, Inc., or the Former Parent, effected the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency, upon which the Former Parent completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of our common stock, or the Distribution. On May 30, 2024, the Former Parent completed a series of internal restructuring transactions, or the Separation.
On May 30, 2024, the Former Parent completed the merger, or the Merger, of Art Acquisition Sub, Inc., a wholly-owned subsidiary of Aventis Inc., or the Acquirer, a wholly-owned subsidiary of Sanofi S.A., or Sanofi, with and into the Former Parent with the Former Parent continuing as the surviving entity.
Quoted from its 10-K, filed 19 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Aug 2020
- Employees
- 109
- Website
- inhibrx.com ↗
- Head office
- 11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Mark LappeChairman of the Board of Director, President, Chief Executive Officer, Co-Founder, since 2010$1.0m
- Dr. Brendan EckelmanCo-Founder, Chief Scientific Officer, since 2010$704,000
- Ms. Kelly DeckChief Financial Officer$1.0m
- Mr. Douglas ForsythIndependent Director$200,950
- Dr. Jon KayyemIndependent Director$190,450
- Ms. Kimberly ManhardIndependent Director$181,950
- Dr. Kristiina VuoriIndependent Director$184,450
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 55
- Environment
- 58
- Social
- 65
- Governance
- 41
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Inhibrx Biosciences Inc employs 109 employees in La Jolla, California for biotechnology research.
- The company's pipeline includes INBRX-109 for chondrosarcoma and mesothelioma cancer treatments.
- Inhibrx has developed a single domain antibody platform for novel biologic therapeutics.
Weaknesses
- Inhibrx Biosciences Inc has 91 full-time employees as of the latest report.
- The company's IPO was on 19 August 2020, showing limited market history.
- Inhibrx's pipeline focuses on specific cancer treatments with limited diversity.
Opportunities
- Inhibrx Biosciences Inc's INBRX-105 targets PD-L1 and 4-1BB for cancer therapy.
- The company's INBRX-101 is in development for Alpha-1 Antitrypsin Deficiency treatment.
- Inhibrx's sdAb platform can be applied to multiple therapeutic areas beyond current pipeline.
Threats
- Inhibrx Biosciences Inc faces competition in the biotechnology sector for cancer treatments.
- The company's focus on specific cancer types may limit market expansion opportunities.
- Regulatory approvals for biologic therapeutics can delay product launches significantly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.